The 2-DG drug has been developed by DRDO’s laboratory, Institute of Nuclear Medicine and Allied Sciences (INMAS) in association with Dr. Reddy Laboratories.
Clinical trial results showed that this molecule helps hospitalized patients recover faster and reduce their dependence on oxygen.
As per the EOI document, applications should be sent through email before June 17. “The EoIs to be given by the industries will be examined by a Technical Assessment Committee (TAC). Only 15 industries will be given ToT on the basis of their capabilities and first come first serve basis.
The bidders should have license to manufacture drugs from active pharmaceutical ingredients (APIs) from drug licensing authorities.